Literature DB >> 21316340

Abnormal expression of ADAR1 isoforms in Chinese pediatric acute leukemias.

Cui-Hua Ma1, Jing-Hui Chong, Ye Guo, Hui-Min Zeng, Shu-Yan Liu, Lin-Lin Xu, Jia Wei, Yong-Min Lin, Xiao-Fan Zhu, Guo-Guang Zheng.   

Abstract

The posttranscriptional RNA editing by the type 1 adenosine deaminase acting on RNAs (ADAR1), expressed as p110 and p150 isoforms, is important for both physiological and pathological processes. Their expression and significance in leukemias remain unknown. Here, we investigated the expression of ADAR1 in Chinese pediatric acute leukemias by real-time PCR and Western blot. The results showed that significant high expression of p110 was detected in leukemias, especially in B-ALL, whereas a slight increase of p150 could be observed. Furthermore, the decrease of p110 expression was observed in B-ALL patients achieving complete remission. Moreover, among prognostic risk groups in ALL, the highest expressions of p110 and p150 were detected in standard-risk group, whereas their lowest expressions were in high-risk group. This observation was further confirmed in comparisons between good and poor prognostic groups based on prognostic related clinical features. These results demonstrated that ADAR1 isoforms showed different expression patterns, suggesting that they might play different roles in pediatric leukemias. Our results will help us for the better understanding of RNA editing, exploring the potential target for the treatment, and making prognostic evaluation in childhood leukemias.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21316340     DOI: 10.1016/j.bbrc.2011.02.025

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  PTBP1 induces ADAR1 p110 isoform expression through IRES-like dependent translation control and influences cell proliferation in gliomas.

Authors:  Bin Yang; Peishan Hu; Xihua Lin; Wei Han; Liyuan Zhu; Xiaochao Tan; Fei Ye; Guanzhou Wang; Fan Wu; Bin Yin; Zhaoshi Bao; Tao Jiang; Jiangang Yuan; Boqin Qiang; Xiaozhong Peng
Journal:  Cell Mol Life Sci       Date:  2015-06-06       Impact factor: 9.261

2.  ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.

Authors:  Qingfei Jiang; Leslie A Crews; Christian L Barrett; Hye-Jung Chun; Angela C Court; Jane M Isquith; Maria A Zipeto; Daniel J Goff; Mark Minden; Anil Sadarangani; Jessica M Rusert; Kim-Hien T Dao; Sheldon R Morris; Lawrence S B Goldstein; Marco A Marra; Kelly A Frazer; Catriona H M Jamieson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-28       Impact factor: 11.205

3.  Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice.

Authors:  Richard A Steinman; Qiong Yang; Maura Gasparetto; Lisa J Robinson; Xiaoping Liu; Diana E Lenzner; Jingzhou Hou; Clayton Smith; Qingde Wang
Journal:  Int J Cancer       Date:  2012-10-17       Impact factor: 7.396

4.  Increased levels of inosine in a mouse model of inflammation.

Authors:  Erin G Prestwich; Aswin Mangerich; Bo Pang; Jose L McFaline; Pallavi Lonkar; Matthew R Sullivan; Laura J Trudel; Koli Taghizedeh; Peter C Dedon
Journal:  Chem Res Toxicol       Date:  2013-04-04       Impact factor: 3.739

5.  Defective quorum sensing of acute lymphoblastic leukemic cells: evidence of collective behavior of leukemic populations as semi-autonomous aberrant ecosystems.

Authors:  Sapan J Patel; Su Dao; Costel C Darie; Bayard D Clarkson
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

6.  MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth.

Authors:  Yael Nemlich; Eyal Greenberg; Rona Ortenberg; Michal J Besser; Iris Barshack; Jasmine Jacob-Hirsch; Elad Jacoby; Eran Eyal; Ludmila Rivkin; Victor G Prieto; Nitin Chakravarti; Lyn M Duncan; David M Kallenberg; Eitan Galun; Dorothy C Bennett; Ninette Amariglio; Menashe Bar-Eli; Jacob Schachter; Gideon Rechavi; Gal Markel
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

7.  An RNA editing fingerprint of cancer stem cell reprogramming.

Authors:  Leslie A Crews; Qingfei Jiang; Maria A Zipeto; Elisa Lazzari; Angela C Court; Shawn Ali; Christian L Barrett; Kelly A Frazer; Catriona H M Jamieson
Journal:  J Transl Med       Date:  2015-02-12       Impact factor: 5.531

Review 8.  Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases.

Authors:  Chunzi Song; Masayuki Sakurai; Yusuke Shiromoto; Kazuko Nishikura
Journal:  Genes (Basel)       Date:  2016-12-17       Impact factor: 4.096

9.  ADAR1-mediated 3' UTR editing and expression control of antiapoptosis genes fine-tunes cellular apoptosis response.

Authors:  Chang-Ching Yang; Yi-Tung Chen; Yi-Feng Chang; Hsuan Liu; Yu-Ping Kuo; Chieh-Tien Shih; Wei-Chao Liao; Hui-Wen Chen; Wen-Sy Tsai; Bertrand Chin-Ming Tan
Journal:  Cell Death Dis       Date:  2017-05-25       Impact factor: 8.469

10.  Nucleoside analog studies indicate mechanistic differences between RNA-editing adenosine deaminases.

Authors:  Rena A Mizrahi; Kelly J Phelps; Andrea Y Ching; Peter A Beal
Journal:  Nucleic Acids Res       Date:  2012-08-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.